David Michael Hyman, MD of Memorial Sloan-Kettering explains common questions physicians ask him concerning his study on the efficacy of larotrectinib (LOXO-101). This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
LBA2501: The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers
Advertisement